Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: Meryl A. Waldman Clear advanced filters

  • There is currently insufficient evidence to recommend screening of kidney allograft donors and recipients for parvovirus B19 infection. As such, physicians managing recipients need to have a high index of suspicion, and include this type of infection in their differential diagnosis of chronic anemia and other cytopenias in the post-transplantation period. Here, Waldman and Kopp from the NIH review the pathogenesis, diagnosis and management of parvovirus B19 infection.

    • Meryl Waldman
    • Jeffrey B Kopp
    Reviews
    Nature Clinical Practice Nephrology
    Volume: 3, P: 540-550

  • Patients with kidney diseases should be prioritized for COVID-19 vaccination and the available data suggest that replication-defective viral-vectored vaccines and mRNA vaccines are safe to use. As vaccine responses are likely to be lower in patients with kidney diseases than in the general population, highly potent vaccines should be preferred.

    • Martin Windpessl
    • Annette Bruchfeld
    • Andreas Kronbichler
    Comments & Opinion
    Nature Reviews Nephrology
    Volume: 17, P: 291-293

  • The nephrologist must consider several difficult questions when faced with a patient who has a new diagnosis of idiopathic membranous nephropathy (IMN). Here, authors from the National Institutes of Health corral the latest trial data to provide an update on the 'who', 'when' and 'how' of IMN treatment. They focus particularly on agents that have been studied as alternatives to cytotoxic drugs and ciclosporin, including mycophenolate mofetil, rituximab and adrenocorticotropic hormone.

    • Meryl Waldman
    • Howard A. Austin III
    Reviews
    Nature Reviews Nephrology
    Volume: 5, P: 469-479